HERVYCTA 440MG

What is HERVYCTA 440MG?

HERVYCTA 440MG is an anti-cancer injection that contains Trastuzumab as its active ingredient. It is a monoclonal antibody designed to target and block the HER2 (Human Epidermal Growth Factor Receptor 2) protein, which is overexpressed in certain breast and gastric cancers.

By binding to the HER2 receptor, HERVYCTA 440MG prevents cancer cells from growing and dividing, thereby slowing down the progression of the disease.

---

What is the Use of HERVYCTA 440MG?

HERVYCTA 440MG is prescribed for:

• HER2-positive breast cancer (early-stage or metastatic)

• HER2-positive gastric or gastroesophageal junction adenocarcinoma

It may be used alone or in combination with other chemotherapy drugs such as paclitaxel, docetaxel, or cisplatin, depending on the treatment protocol.

---

Benefits of HERVYCTA 440MG

• Targeted cancer therapy that directly attacks HER2-positive cells.

• Improves overall survival and reduces cancer recurrence risk.

• Reduces tumor growth and prevents metastasis.

• Can be combined safely with standard chemotherapy for enhanced effectiveness.

---

How HERVYCTA 440MG Works

HERVYCTA 440MG (Trastuzumab) attaches to HER2 receptors on the surface of cancer cells. This blocks the growth signals that promote cell division and stimulates the immune system to destroy the cancerous cells.

---

Side Effects of HERVYCTA 440MG

Common Side Effects:

• Fever or chills

• Headache

• Nausea, vomiting, or diarrhea

• Fatigue

• Muscle or joint pain

• Rash or itching

Serious Side Effects (seek medical help immediately):

• Heart-related issues (heart failure or irregular heartbeat)

• Severe allergic reactions

• Breathing difficulty or cough

• Liver or lung problems

---

Precautions & Warnings

• Use only under the supervision of an oncologist.

• Monitor cardiac function before and during treatment.

• Avoid use during pregnancy or breastfeeding.

• Inform your doctor about any history of heart, liver, or lung disease.

• Do not self-administer this medicine.

---

Storage & Administration

• Store between 2°C – 8°C (Refrigerated).

• Do not freeze or shake the vial.

• Administered as an intravenous (IV) infusion by a healthcare professional.

---

Product Summary

• Product Name: HERVYCTA 440MG Injection

• Salt Name: Trastuzumab

• Strength: 440 mg

• Manufacturer: Hetero Healthcare Ltd.

• Storage: Store at 2°C – 8°C (Refrigerated). Do not freeze.

• Presentation: Single-use vial for intravenous infusion

1. What is HERVYCTA 440MG used for?
It is used to treat HER2-positive breast and gastric cancers.

2. What is the active ingredient in HERVYCTA 440MG?
The active ingredient is Trastuzumab.

3. How does HERVYCTA 440MG work?
It binds to HER2 receptors, blocking growth signals and helping the immune system destroy cancer cells.

4. How is HERVYCTA 440MG administered?
It is given as an intravenous infusion under medical supervision.

5. How often is HERVYCTA 440MG given?
Usually every 1 to 3 weeks, depending on your oncologist’s prescription.

6. Can HERVYCTA 440MG be used alone?
Yes, or in combination with chemotherapy, depending on cancer stage.

7. What are the common side effects?
Fever, chills, nausea, headache, diarrhea, and fatigue.

8. Can it cause heart problems?
Yes, it can cause cardiac issues; regular heart monitoring is required.

9. Is it safe during pregnancy?
No, it should not be used during pregnancy or breastfeeding.

10. What should I do if I miss a dose?
Contact your doctor immediately to reschedule the infusion.

11. How long does HERVYCTA treatment last?
Treatment duration varies, typically between 6 months and 1 year.

12. Can it be taken with other cancer drugs?
Yes, but only under your oncologist’s supervision.

13. How should it be stored?
Refrigerate between 2°C–8°C. Do not freeze or expose to sunlight.

14. Who should not use HERVYCTA 440MG?
Patients with severe heart or lung conditions should avoid it unless advised by a doctor.

15. Who manufactures HERVYCTA 440MG?
It is manufactured by Hetero Healthcare Ltd., a leading oncology medicine producer.